Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "ADC"

156 News Found

PM dedicates AIIMS Nagpur to the nation
Policy | December 12, 2022

PM dedicates AIIMS Nagpur to the nation

The hospital is being developed at a cost of more than Rs. 1,575 crore


Briefs: Piramal Enterprises and Shilpa Medicare
News | December 02, 2022

Briefs: Piramal Enterprises and Shilpa Medicare

Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval


Lonza collaborates with AbTis to extend Bioconjugation capabilities
Biotech | November 30, 2022

Lonza collaborates with AbTis to extend Bioconjugation capabilities

Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox


Lonza and Singzyme to accelerate development of Bioconjugates
News | November 01, 2022

Lonza and Singzyme to accelerate development of Bioconjugates

Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest


Carbogen Amcis completes Swissmedic inspection of its facility in Vionnaz, Switzerland
News | September 28, 2022

Carbogen Amcis completes Swissmedic inspection of its facility in Vionnaz, Switzerland

This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.


Balaxi Pharma to issue Rs. 49.61 crore Equity Shares/Warrants
News | September 06, 2022

Balaxi Pharma to issue Rs. 49.61 crore Equity Shares/Warrants

Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ


Ashland to expand bioresorbable polymers capacity in Ireland
News | September 02, 2022

Ashland to expand bioresorbable polymers capacity in Ireland

The capital expansion program commenced in June 2022 and is expected to complete in 2024


Merck, Starpharma expand partnership to develop antibody drug conjugates
Diagnostic Center | August 19, 2022

Merck, Starpharma expand partnership to develop antibody drug conjugates

DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i


ENHERTU delays disease progression in DESTINYBreast02 Phase 3 Trial
Diagnostic Center | August 15, 2022

ENHERTU delays disease progression in DESTINYBreast02 Phase 3 Trial

Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients


Arbitrator rules in favor of Daiichi Sankyo in dispute with Seagen
News | August 15, 2022

Arbitrator rules in favor of Daiichi Sankyo in dispute with Seagen

All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied